IL162602A0 - Pyrrolidine derivatives as prostaglandin modulators - Google Patents
Pyrrolidine derivatives as prostaglandin modulatorsInfo
- Publication number
- IL162602A0 IL162602A0 IL16260202A IL16260202A IL162602A0 IL 162602 A0 IL162602 A0 IL 162602A0 IL 16260202 A IL16260202 A IL 16260202A IL 16260202 A IL16260202 A IL 16260202A IL 162602 A0 IL162602 A0 IL 162602A0
- Authority
- IL
- Israel
- Prior art keywords
- compounds
- disorder
- substituted pyrrolidine
- pyrrolidine derivatives
- prostaglandin
- Prior art date
Links
- 150000003180 prostaglandins Chemical class 0.000 title abstract 2
- 150000003235 pyrrolidines Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000020084 Bone disease Diseases 0.000 abstract 2
- 208000021267 infertility disease Diseases 0.000 abstract 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 2
- 208000005171 Dysmenorrhea Diseases 0.000 abstract 1
- 206010013935 Dysmenorrhoea Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 abstract 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000023555 blood coagulation Effects 0.000 abstract 1
- 230000001066 destructive effect Effects 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 208000002296 eclampsia Diseases 0.000 abstract 1
- 208000012610 eosinophil disease Diseases 0.000 abstract 1
- 230000036512 infertility Effects 0.000 abstract 1
- 231100000535 infertility Toxicity 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 abstract 1
- 201000011461 pre-eclampsia Diseases 0.000 abstract 1
- -1 pyrrolidine compound Chemical class 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34262001P | 2001-12-20 | 2001-12-20 | |
| PCT/EP2002/014593 WO2003053923A2 (en) | 2001-12-20 | 2002-12-19 | Pyrrolidine derivatives as prostaglandin modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL162602A0 true IL162602A0 (en) | 2005-11-20 |
Family
ID=23342570
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16260202A IL162602A0 (en) | 2001-12-20 | 2002-12-19 | Pyrrolidine derivatives as prostaglandin modulators |
| IL162602A IL162602A (en) | 2001-12-20 | 2004-06-17 | Pyrrolidine derivatives as prostaglandin modulators |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL162602A IL162602A (en) | 2001-12-20 | 2004-06-17 | Pyrrolidine derivatives as prostaglandin modulators |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7335680B2 (https=) |
| EP (1) | EP1458679B1 (https=) |
| JP (1) | JP4554931B2 (https=) |
| AT (1) | ATE455758T1 (https=) |
| AU (2) | AU2002358772B2 (https=) |
| CA (1) | CA2469075C (https=) |
| DE (1) | DE60235198D1 (https=) |
| ES (1) | ES2337887T3 (https=) |
| IL (2) | IL162602A0 (https=) |
| WO (1) | WO2003053923A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60235198D1 (de) * | 2001-12-20 | 2010-03-11 | Merck Serono Sa Coinsins | Pyrrolidin-derivatie als prostaglandin-modulatoren |
| ES2584606T3 (es) | 2002-10-10 | 2016-09-28 | Ono Pharmaceutical Co., Ltd. | Microesferas que comprenden ONO-1301 |
| KR100843244B1 (ko) | 2007-04-19 | 2008-07-02 | 삼성전자주식회사 | 반도체 소자 및 그 제조 방법 |
| WO2006052893A2 (en) | 2004-11-08 | 2006-05-18 | Allergan, Inc. | Substituted pyrrolidone compounds as ep4 agonists |
| US7893107B2 (en) | 2005-11-30 | 2011-02-22 | Allergan, Inc. | Therapeutic methods using prostaglandin EP4 agonist components |
| US7557095B2 (en) * | 2006-05-12 | 2009-07-07 | Allergan, Inc. | Therapeutic compounds |
| US7550448B2 (en) * | 2006-05-24 | 2009-06-23 | Allergan, Inc. | Therapeutic compounds |
| EP2147672A4 (en) | 2007-05-08 | 2011-11-02 | Nat University Corp Hamamatsu University School Of Medicine | CYTOTOXIC T CELL ACTIVATOR WITH AN EP4 AGONIST |
| SI2155733T1 (sl) * | 2007-05-23 | 2012-12-31 | Allergan, Inc | Ciklični laktami za zdravljenje glavkoma ali zvišanega očesnega tlaka |
| US7964596B2 (en) * | 2008-03-07 | 2011-06-21 | Allergan, Inc. | Therapeutic compounds |
| EP2149551A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors |
| EP2149554A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma Aktiengesellschaft | Indolylamide als Modulatoren des EP2-Rezeptors |
| EP2149552A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors |
| GEP20125607B (en) * | 2008-11-10 | 2012-08-10 | Pfizer Ltd | Pyrrolidines |
| JPWO2010087425A1 (ja) | 2009-01-30 | 2012-08-02 | 国立大学法人京都大学 | 前立腺癌の進行抑制剤および進行抑制方法 |
| TW201326154A (zh) | 2011-11-28 | 2013-07-01 | 拜耳知識產權公司 | 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑 |
| ES2733998T3 (es) | 2012-10-29 | 2019-12-03 | Cardio Incorporated | Agente terapéutico específico de enfermedad pulmonar |
| US9968716B2 (en) | 2013-10-15 | 2018-05-15 | Ono Pharmaceutical Co., Ltd. | Drug-eluting stent graft |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3873566A (en) * | 1973-02-28 | 1975-03-25 | Du Pont | 3-Pyrazolidinones and pyrazolidines |
| DE2451160A1 (de) * | 1973-10-30 | 1975-05-07 | Du Pont | 3-pyrazolidinone und pyrazolidine |
| US3976660A (en) * | 1974-08-15 | 1976-08-24 | E. R. Squibb & Sons, Inc. | Pyrrolidine derivatives |
| DE2527989A1 (de) | 1975-06-24 | 1977-01-27 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
| US4033989A (en) | 1975-09-17 | 1977-07-05 | The Upjohn Company | 9-Deoxy-PGF2 Analogs |
| US4003911A (en) * | 1975-09-26 | 1977-01-18 | E. I. Du Pont De Nemours And Company | Selected 3-pyrrolidinones and 2,4-pyrrolidindiones |
| US4090019A (en) | 1976-05-10 | 1978-05-16 | Minnesota Mining And Manufacturing Company | Geminal prostaglandin analogs |
| US4211876A (en) * | 1979-06-13 | 1980-07-08 | E. I. Du Pont De Nemours And Company | 3-Pyrazolidinone carboxamides |
| US4753945A (en) | 1986-02-19 | 1988-06-28 | Eye Research Institute Of Retina Foundation | Stimulation of tear secretion with phosphodiesterase inhibitors |
| US5091431A (en) | 1988-02-08 | 1992-02-25 | Schering Corporation | Phosphodiesterase inhibitors |
| US5010086A (en) | 1990-02-28 | 1991-04-23 | Sterling Drug Inc. | Imidazopyridines, compositions and use |
| GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
| GB9119704D0 (en) | 1991-09-14 | 1991-10-30 | Pfizer Ltd | Therapeutic agents |
| GB9121028D0 (en) | 1991-10-03 | 1991-11-13 | Pfizer Ltd | Therapeutic agents |
| GB9126260D0 (en) | 1991-12-11 | 1992-02-12 | Pfizer Ltd | Therapeutic agents |
| GB9213623D0 (en) | 1992-06-26 | 1992-08-12 | Pfizer Ltd | Therapeutic agents |
| GB9218322D0 (en) | 1992-08-28 | 1992-10-14 | Pfizer Ltd | Therapeutic agents |
| US5605814A (en) | 1993-08-31 | 1997-02-25 | Merck Frosst Canada Inc. | DNA encoding human prostaglandin receptor EP2 |
| US6143746A (en) | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
| GB9514465D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
| GB9514160D0 (en) | 1994-07-25 | 1995-09-13 | Zeneca Ltd | Aromatic compounds |
| GB9417532D0 (en) | 1994-08-31 | 1994-10-19 | Zeneca Ltd | Aromatic compounds |
| GB9423911D0 (en) | 1994-11-26 | 1995-01-11 | Pfizer Ltd | Therapeutic agents |
| TW434240B (en) | 1995-06-20 | 2001-05-16 | Zeneca Ltd | Aromatic compounds, preparation thereof and pharmaceutical composition comprising same |
| TW502026B (en) | 1995-06-20 | 2002-09-11 | Zeneca Ltd | Aromatic compounds useful as antagonists of e-type prostaglandins, processes for the preparation thereof, pharmaceutical compositions comprising the compounds, and intermediates |
| EP0752421B1 (en) | 1995-07-07 | 2005-10-12 | AstraZeneca AB | Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists |
| GB9514464D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
| GB9514473D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
| ES2175404T3 (es) | 1996-05-10 | 2002-11-16 | Icos Corp | Derivados de carbolina. |
| EP0941221B1 (en) | 1996-11-20 | 2003-02-26 | ALTANA Pharma AG | Substituted dihydrobenzofurans as pde inhibitors |
| UA59384C2 (uk) | 1996-12-20 | 2003-09-15 | Пфайзер, Інк. | Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі |
| AT404730B (de) * | 1997-04-07 | 1999-02-25 | Holderchem Ag | Acryl-copolymere und polymerzusammensetzungen sowie deren verwendung als additive oder beimischungen zur verbesserung der eigenschaften von dispersionen und baustoffen |
| US6043252A (en) | 1997-05-05 | 2000-03-28 | Icos Corporation | Carboline derivatives |
| JP2001510827A (ja) | 1997-07-25 | 2001-08-07 | ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | 置換６−フェニルフェナントリジン |
| US6006735A (en) | 1997-09-12 | 1999-12-28 | Park Industries, Inc. | Automated stoneworking system and method |
| US6156753A (en) | 1997-10-28 | 2000-12-05 | Vivus, Inc. | Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| US6127363A (en) | 1997-10-28 | 2000-10-03 | Vivus, Inc. | Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| GB9725953D0 (en) | 1997-12-08 | 1998-02-04 | Pfizer Ltd | Compounds useful in therapy |
| US6211197B1 (en) | 1998-10-07 | 2001-04-03 | Merck Frosst Canada & Co. | Prostaglandin receptor ligands |
| GB9822238D0 (en) | 1998-10-12 | 1998-12-09 | Pfizer Ltd | Process for preparation of pyrazolo[4,3-D]pyrimidin-7-ones and intermediates thereof |
| GEP20043203B (en) * | 1999-12-22 | 2004-03-25 | Pfizer Prod Inc | EP4 Receptor Selective Agonists in the Treatment of Osteoporosis |
| CA2451392A1 (en) * | 2001-07-16 | 2003-01-30 | F. Hoffmann-La Roche Ag | Prostaglandin analogues as ep4 receptor agonists |
| DE60235198D1 (de) * | 2001-12-20 | 2010-03-11 | Merck Serono Sa Coinsins | Pyrrolidin-derivatie als prostaglandin-modulatoren |
-
2002
- 2002-12-19 DE DE60235198T patent/DE60235198D1/de not_active Expired - Lifetime
- 2002-12-19 ES ES02793091T patent/ES2337887T3/es not_active Expired - Lifetime
- 2002-12-19 IL IL16260202A patent/IL162602A0/xx unknown
- 2002-12-19 US US10/499,346 patent/US7335680B2/en not_active Expired - Fee Related
- 2002-12-19 AU AU2002358772A patent/AU2002358772B2/en not_active Ceased
- 2002-12-19 JP JP2003554640A patent/JP4554931B2/ja not_active Expired - Fee Related
- 2002-12-19 WO PCT/EP2002/014593 patent/WO2003053923A2/en not_active Ceased
- 2002-12-19 AT AT02793091T patent/ATE455758T1/de not_active IP Right Cessation
- 2002-12-19 CA CA2469075A patent/CA2469075C/en not_active Expired - Fee Related
- 2002-12-19 EP EP02793091A patent/EP1458679B1/en not_active Expired - Lifetime
-
2004
- 2004-06-17 IL IL162602A patent/IL162602A/en not_active IP Right Cessation
-
2007
- 2007-11-21 US US11/943,684 patent/US7635713B2/en not_active Expired - Fee Related
-
2009
- 2009-02-19 AU AU2009200663A patent/AU2009200663B2/en not_active Ceased
- 2009-08-03 US US12/534,292 patent/US8058305B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1458679B1 (en) | 2010-01-20 |
| WO2003053923A3 (en) | 2004-01-29 |
| ATE455758T1 (de) | 2010-02-15 |
| US7635713B2 (en) | 2009-12-22 |
| IL162602A (en) | 2011-07-31 |
| DE60235198D1 (de) | 2010-03-11 |
| AU2002358772A1 (en) | 2003-07-09 |
| ES2337887T3 (es) | 2010-04-30 |
| US20050176800A1 (en) | 2005-08-11 |
| JP4554931B2 (ja) | 2010-09-29 |
| WO2003053923A2 (en) | 2003-07-03 |
| US20090292000A1 (en) | 2009-11-26 |
| AU2002358772B2 (en) | 2008-11-20 |
| US20080114051A1 (en) | 2008-05-15 |
| US8058305B2 (en) | 2011-11-15 |
| AU2009200663B2 (en) | 2011-09-15 |
| US7335680B2 (en) | 2008-02-26 |
| CA2469075A1 (en) | 2003-07-03 |
| CA2469075C (en) | 2011-09-13 |
| EP1458679A2 (en) | 2004-09-22 |
| JP2005517665A (ja) | 2005-06-16 |
| AU2009200663A1 (en) | 2009-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL162602A0 (en) | Pyrrolidine derivatives as prostaglandin modulators | |
| IL161581A0 (en) | Pyrazolidinone derivatives and their use | |
| MA27556A1 (fr) | Derives de phenylalanine comme inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete | |
| NO20030895L (no) | Ny anvendelse av dipeptidyl peptidase IV inhibitorer | |
| EP1485381B8 (en) | Azolylaminoazine as inhibitors of protein kinases | |
| NO20040331L (no) | Legemidler for sykdommer med benmassetap som har Eragonist som den aktive bestanddel | |
| UA48939C2 (uk) | Дизаміщені фуранони, способи їх одержання, фармацевтична композиція на їх основі, спосіб лікування запального захворювання, проміжні сполуки | |
| EP1651623A4 (en) | HEXAHYDRODIAZEPINONE AS INHIBITORS OF DIPEPTIDYLPEPTIDASE-IV FOR TREATMENT OR PREVENTION OF DIABETES | |
| YU18400A (sh) | Prostaglanidin agonisti i njihova primena za tretiranje koštanih poremećaja | |
| AU2003220299A1 (en) | Azinylaminoazoles as inhibitors of protein kinases | |
| AU2003218215A1 (en) | Azolylaminoazines as inhibitors of protein kinases | |
| WO2003057666A3 (en) | Inhibitors of dipeptidyl peptidase iv | |
| AU2002305450A1 (en) | Proteomimetic compounds and methods | |
| ATE451376T1 (de) | Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen | |
| TW200633980A (en) | Pyridones useful as inhibitors of kinases | |
| NZ514449A (en) | Compositions for improving fertility using a dipeptidyl peptidase IV inhibitor | |
| WO2004050022A8 (en) | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | |
| AU5584901A (en) | Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease | |
| WO2003013430A3 (en) | Benzoquinone ansamycins | |
| AU2002363182A1 (en) | Smad7 inhibitors for the treatment of cns diseases | |
| NO20050851L (no) | Kaspase-inhibitorer og anvendelser derav | |
| TNSN04015A1 (en) | Combination therapy for the treatment of cancer | |
| MXPA05004621A (es) | Derivados de anilinopirazol utiles en el tratamiento de la diabetes. | |
| PL334500A1 (en) | Methods of therapeutically administering substances acting against cd40l | |
| IL179206A0 (en) | Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same |